<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889211</url>
  </required_header>
  <id_info>
    <org_study_id>16060315</org_study_id>
    <nct_id>NCT02889211</nct_id>
  </id_info>
  <brief_title>Brain Function in Depression and Insulin Resistance</brief_title>
  <official_title>Brain Function in Depression and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help researchers learn about how the brain responds to
      rewards. This study is interested in seeing how these responses differ between people who are
      more and less responsive to insulin in their body, and people with and without depression.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator Left University
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI BOLD Response in Striatal Regions</measure>
    <time_frame>During Gambling Task in fMRI Scanner</time_frame>
    <description>The investigators will monitor the blood oxygen level dependent response using fMRI and compare activation during &quot;win&quot; trials vs. &quot;loss&quot; trials</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Depression</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metabolically Healthy - Non-depressed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Overweight individuals without metabolic syndrome and free of psychiatric illness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metabolically Healthy - Depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals without metabolic syndrome and with active major depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Resistant - Depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals with metabolic syndrome and active major depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Resistant - Non-depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overweight individuals with metabolic syndrome and free of psychiatric illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Gambling Task</intervention_name>
    <arm_group_label>Metabolically Healthy - Non-depressed</arm_group_label>
    <arm_group_label>Metabolically Healthy - Depressed</arm_group_label>
    <arm_group_label>Insulin Resistant - Depressed</arm_group_label>
    <arm_group_label>Insulin Resistant - Non-depressed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Body Mass Index 24-34.9

        HEALTHY CONTROLS HOMA-IR (fasting (glucose x insulin)/405) &lt; 1.8

        Not more than one of the following:

          -  Waist circumference &gt; 40 inches (men) or &gt; 35 inches (women)

          -  Triglycerides &gt; 150 mg/dL

          -  HDL &lt; 40 mg/dL (men) or &lt; 50 mg/dL (women)

          -  Blood pressure &gt; 135/85

          -  Fasting glucose &gt; 100 mg/dL

        INSULIN RESISTANT HOMA-IR &gt; 2.0

        And at least three of the following:

          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)

          -  Triglycerides &gt; 150 mg/dL

          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)

          -  Blood pressure &gt; 135/85

          -  Fasting glucose &gt; 100 mg/dL

        MAJOR DEPRESSION, METABOLICALLY HEALTHY Meets criteria for MDD during SCID-5 evaluation
        HOMA-IR &lt; 1.8

        Not more than one of the following:

          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)

          -  Triglycerides &gt; 150 mg/dL

          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)

          -  Blood pressure &gt; 135/85

          -  Fasting glucose &gt; 100 mg/dL

        MAJOR DEPRESSION, INSULIN RESISTANT Meets criteria for MDD during SCID-5 evaluation HOMA-IR
        &gt; 2.0

        And at least three of the following:

          -  Waist circumference &gt; 40 inches (men) or &gt;35 inches (women)

          -  Triglycerides &gt; 150 mg/dL

          -  HDL &lt; 40 mg/dL (men) or &lt;50 mg/dL (women)

          -  Blood pressure &gt; 135/85

          -  Fasting glucose &gt; 100 mg/dL

        Exclusion Criteria:

          -  - History of mania or psychosis

          -  Current suicidal ideation

          -  Alcohol or substance abuse including cannabis use (current or in the last three
             months)

          -  Early onset dementia of any etiology

          -  Medical conditions with known significant effects on mood (e.g. Stroke or current
             hypothyroid state)

          -  Unstable medical illnesses (e.g. Delirium, uncontrolled DM, uncontrolled
             cardiovascular illness)

          -  Use of high doses of benzodiazepines (&gt; 2mg lorazepam/day equivalent)

          -  Given the high comorbidity (80%) between MDD and anxiety disorders, participants with
             comorbid anxiety disorders will be included in the study as long as the clinical
             presentation suggests that depression precedes the onset of anxiety

          -  Current or lifetime history of cancer, a chronic kidney or liver condition, type I or
             II diabetes

          -  Current or lifetime use of glucocorticoid medications for &gt;1 month

          -  Previous cerebrovascular accident or trauma involving loss of consciousness

          -  Previous neurosurgery or history of a neurological condition

          -  Pregnancy (females)

          -  Claustrophobia

          -  Ferrous metallic implants or any surgically placed medical device not cleared for
             safety at 3Tesla MRI strength

          -  Positive Hepatitis C serology or other known viral infections that may induce insulin
             resistance

          -  Peripheral vascular disease

          -  Liver, kidney, or active blood disease

          -  Peripheral neuropathy

          -  Fasting glucose &gt; 126 mg/dL

          -  Currently taking any medications that can alter glucose homeostasis (steroids,
             glucocorticoids, nicotinic acid)

          -  Currently taking thiazolidinediones or insulin

          -  Females currently on hormone replacement therapy (HRT) less than 6 months

          -  Being left handed

          -  Use of antidepressant medication within the past two weeks (six weeks fluoxetine)

          -  Suicide risk

          -  Current use of stimulants, antipsychotic medications, mood stabilizers, cognitive
             enhancers, statins, glucocorticoids, steroids, nicotinic acid, thiazolidinediones,
             insulin, metformin, any diabetes medications (e.g. gliptins), HIV medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic at University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>December 2, 2017</last_update_submitted>
  <last_update_submitted_qc>December 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>John Patrick Ryan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

